Coronavirus Update: Pfizer/BioNTech Vaccine Shows Six-Month, Variant Protection
The companies still plan to develop a variant-specific version, while J&J said it anticipates meeting vaccine supply goals despite a manufacturing mix-up.
You may also be interested in...
An EUA would carve out a market advantage, although Moderna should be releasing similar data soon for its COVID-19 vaccine.
Plus Pfizer/BioNTech report real-world data from Israel on its vaccine, while Roche’s Actemra misses Phase III endpoint in another combo study with Veklury.
Broader than initially reported, Merck & Co.’s agreement with BARDA extends beyond J&J’s recently authorized vaccine to other COVID-19 vaccines and therapeutics as needed.